Utama › Kanser Ovari › Minnesota › Rochester
Kajian klinikal Kanser Ovari di Rochester, MN
29 kajian untuk Kanser Ovari sedang mencari peserta di lokasi dalam dan sekitar Rochester (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Mengambil pesertaFasa 2/3
- Mayo Clinic in Rochester, Rochester
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mengambil pesertaFasa 2
- Mayo Clinic in Rochester, Rochester
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mengambil pesertaKajian pemerhatian
- Mayo Clinic, Rochester
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Mengambil peserta
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
- Mayo Clinic Rochester, Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Mengambil pesertaFasa 1/2
- Mayo Clinic - Rochester, Rochester
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Mengambil pesertaFasa 3
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Mengambil pesertaFasa 1
- Mayo Clinic - Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Mengambil pesertaFasa 1/2
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
- Mayo Clinic (Rochester), Rochester
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Mengambil peserta
- Mayo Clinic in Rochester, Rochester
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Mayo Clinic in Rochester, Rochester
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Mayo Clinic (Minnesota), Rochester
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Mengambil pesertaFasa 3
- Mayo Clinic Methodist Campus, Rochester
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Mengambil pesertaFasa 2
- Mayo Clinic, Rochester
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Mengambil pesertaFasa 1/2
- The Mayo Clinic, Rochester
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Mengambil pesertaFasa 1
- Mayo Clinic, Rochester
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Mengambil pesertaFasa 1/2
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- Mayo Clinic - Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Mengambil peserta
- Mayo Clinic, Rochester
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Mengambil pesertaFasa 3
- Mayo Clinic, Rochester
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Mengambil peserta
- Mayo Clinic, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Mengambil pesertaFasa 1/2
- Mayo Clinic, Rochester
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Mengambil pesertaFasa 1
- Mayo Clinic in Rochester, Rochester
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Mengambil peserta
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Mayo Clinic, Rochester
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Mengambil pesertaFasa 2
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #14, Rochester
Kajian Kanser Ovari di bandar lain
- Houston, TX89 kajian
- New York City, NY69 kajian
- Boston, MA61 kajian
- Los Angeles, CA50 kajian
- Nashville, TN49 kajian
- Arlington, VA46 kajian
- Philadelphia, PA44 kajian
- Columbus, OH39 kajian
- St. Louis, MO38 kajian
- Chicago, IL36 kajian
- San Antonio, TX31 kajian
- Cleveland, OH30 kajian
Kajian lain di Rochester
- Kanser Payudara42 kajian
- Kanser Paru-paru Bukan Sel Kecil37 kajian
- Kanser Metastatik31 kajian
- Kanser (semua jenis)30 kajian
- Kanser Kolorektal29 kajian
- Mieloma Pelbagai24 kajian
- Kegagalan Jantung22 kajian
- Kanser Prostat22 kajian
- Kanser Pankreas22 kajian
- Kanser Endometrium20 kajian
- Kanser Paru-paru20 kajian
- Leukemia Limfositik Kronik18 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.